MN/CA9: a potential gene marker for detection of malignant cells in effusions

References

• Bedrossian, CWM. 1998. Diagnostic problems in serous effusions. Diagnostic Cytopathology, 19:131–137.
   PubMedGoogle Scholar
• Buhr J, Berghauser KH, Gonner S, Kelm C, Burkhardt E, Padberg WM. The prognostic significance of tumor cell detection in intraoperative pleural lavage and lung tissue culture with lung cancer. Journal of Thorac Cardiovascular Surgery 1997; 113: 683–690
   PubMedGoogle Scholar
• Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. Journal of Clinical Oncology 2001; 19: 3660–3668
   PubMed Web of Science ®Google Scholar
• Fetsch PA, Abati A. Immunocytochemistry in effusion cytology: a contemporary review. Cancer 2001; 93: 293–308
   PubMed Web of Science ®Google Scholar
• Fiegl M, Haun M, Massoner A, Krugmann J, Muller-Holzner E, Hack R, et al. Combination of cytology, fluorescence in situ hybridization for aneuploidy, and reverse-transcriptase polymerase chain reaction for human mammaglobin/mammaglobin B expression improves diagnosis of malignant effusions. Journal of Clinical Oncology 2004; 22: 474–483
   PubMedGoogle Scholar
• Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, et al. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. Journal of Clinical Oncology 1994; 12: 725–729
   PubMed Web of Science ®Google Scholar
• Hedley D, Pintilie M, Woo J, Morrison A, Birle D, Fyles A, et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clinical Cancer Research 2003; 9: 5666–5674
   PubMed Web of Science ®Google Scholar
• Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. American Journal of Pathology 2001; 158: 905–919
   PubMed Web of Science ®Google Scholar
• Kim SJ, Rabbani ZN, Vollmer RT, Schreiber EG, Oosterwijk E, Dewhirst MW, et al. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clinical Cancer Research 2004; 10: 7925–7933
   PubMedGoogle Scholar
• Kivela AJ, Parkkila S, Saarnio J, Karttunen TJ, Kivela J, Parkila AK, et al. Expression of von Hippel–Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa. World Journal of Gastroenterology 2005; 11: 2616–2625
   PubMed Web of Science ®Google Scholar
• Kowalewska M, Radziszewski J, Kulik J, Barathova M, Nasierowska-Guttmajer A, Bidzinski M, et al. Detection of carbonic anhydrase 9-expressing tumor cells in the lymph nodes of vulvar carcinoma patients by RT-PCR. International Journal of Cancer 2005; 116: 957–962
   PubMed Web of Science ®Google Scholar
• Lee WY. Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination. Cytopathology 2005; 16: 227–232
   PubMed Web of Science ®Google Scholar
• Li G, Cuilleron M, Cottier M, Gentil-Perret A, Lambert C, Genin C, et al. The use of MN/CA9 gene expression in identifying malignant solid renal tumors. European Urology 2006; 49: 401–405
   PubMed Web of Science ®Google Scholar
• Li G, Passebosc-Faure K, Lambert C, Gentil-Perret A, Blanc F, Oosterwijk E, et al. The expression of G250/MN/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells. Clinical Cancer Research 2001; 7: 89–92
   PubMed Web of Science ®Google Scholar
• Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Research 1997; 57: 2827–2833
   PubMed Web of Science ®Google Scholar
• Light RW. Tumor markers in undiagnosed pleural effusions. Chest 2004; 126: 1721–1722
   PubMedGoogle Scholar
• Lloyd JM, Mclver CM, Stephenson SA, Hewett PJ, Rieger N, Hardingham JE. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clinical Cancer Research 2006; 12: 417–423
   PubMed Web of Science ®Google Scholar
• McKiernan JM, Buttyan R, de la Taille A, Stifelman MD, Emanuel ER, Bagiella E, et al. The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase polymerase chain reaction assay for MN/CA9. Cancer 1999; 86: 492–497
   PubMed Web of Science ®Google Scholar
• Mohanty SK, Dey P. Serous effusions: diagnosis of malignancy beyond cytomorphology. An analytic review. Postgraduate Medical Journal 2003; 79: 569–574
   PubMed Web of Science ®Google Scholar
• Monte SA, Ehya H, Lang WR. Positive effusion cytology as the initial presentation of malignancy. Acta Cytologica 1987; 31: 448–452
   PubMed Web of Science ®Google Scholar
• Mori M, Mimori K, Ueo H, Tsuj K, Shiraishi T, Barnard GF, et al. Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription-polymerase chain reaction in patients with gastrointestinal or breast carcinomas. Journal of Clinical Oncology 1998; 16: 128–132
   PubMedGoogle Scholar
• Nagel H, Werner C, Hemmerlein B. Real-time reverse transcription-polymerase chain reaction assay for GA733-2 m RNA in the detection of metastatic carcinoma cells in serous effusions. American Journal of Clinical Pathology 2003; 120: 888–901
   PubMedGoogle Scholar
• Okamoto I, Morisaki T, Sasaki J, Miyake H, Matsumoto M, Suga M, et al. Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs. Journal of the National Cancer Institute 1998; 90: 307–315
   PubMedGoogle Scholar
• Passebosc-Faure K, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, et al. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clinical Cancer Research 2005; 11: 6862–6867
   PubMed Web of Science ®Google Scholar
• Porcel JM, Vives M, Esquerdas A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of malignant and benign effusions). Chest 2004; 126: 1757–1763
   PubMed Web of Science ®Google Scholar
• Potter CP, Harris AJ. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. British Journal of Cancer 2003; 89: 2–7
   PubMed Web of Science ®Google Scholar
• Shitrit D, Zingerman B, Bar-Gil Shitrit A, Shlomi D, Kramer MR. Diagnostic value of CYFRA 21-1, CEA, CA19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. The Oncologists 2005; 10: 501–507
   PubMed Web of Science ®Google Scholar
• To EM, Chan WY, Chow C, Ng EK, Chung SC. Gastric cancer cell detection in peritoneal washing: cytology versus RT-PCR for CEA transcripts. Diagnostic Molecular Pathology 2003; 12: 88–95
   PubMedGoogle Scholar
• Yang CT, Lee MH, Lan RS, Chen JK. Telomerase activity in pleural effusions: diagnostic significance. Journal of Clinical Oncology 1998; 16: 567–573
   PubMed Web of Science ®Google Scholar
• Yu CJ, Shew JY, Liaw YS, Kuo SH, Luh KT, et al. Application of mucin quantitative competitive reverse transcription polymerase chain reaction in assisting the diagnosis of malignant pleural effusion. American Journal of Respiratory and Critical Care Medicine 2001; 164: 1312–1318
   PubMedGoogle Scholar